Comprehensive Financial Consultants Institutional Inc. Increases Stake in DexCom, Inc. (NASDAQ:DXCM)

Comprehensive Financial Consultants Institutional Inc. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 13.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,334 shares of the medical device company’s stock after purchasing an additional 874 shares during the quarter. Comprehensive Financial Consultants Institutional Inc.’s holdings in DexCom were worth $492,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. AlphaCentric Advisors LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at $280,000. Quintet Private Bank Europe S.A. grew its position in DexCom by 324.1% during the third quarter. Quintet Private Bank Europe S.A. now owns 4,105 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 3,137 shares during the period. QRG Capital Management Inc. increased its stake in DexCom by 8.6% during the third quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock worth $1,052,000 after acquiring an additional 1,248 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in shares of DexCom by 10.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 235,474 shares of the medical device company’s stock worth $15,786,000 after purchasing an additional 22,268 shares during the period. Finally, National Pension Service lifted its stake in shares of DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

DexCom Stock Up 0.4 %

DXCM stock opened at $68.91 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a 50 day simple moving average of $69.65 and a 200-day simple moving average of $94.12. The company has a market capitalization of $26.92 billion, a P/E ratio of 41.26, a PEG ratio of 2.14 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Wells Fargo & Company increased their price objective on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Morgan Stanley reduced their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Finally, Robert W. Baird raised their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.